Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | Backbone antiretroviral also active against hepatitis B. | Backbone drug for HIV treatment, PrEP and hepatitis B. |
| Body system | Antivirals | Antivirals |
| Drug class | Nucleos(t)ide reverse transcriptase inhibitors | Nucleos(t)ide reverse transcriptase inhibitors |
| Supply | Prescription onlyWHO essential medicine | Prescription onlyWHO essential medicine |
| Main uses | HIV infection (with other drugs), Chronic hepatitis B | HIV treatment, HIV pre-exposure prophylaxis (PrEP, with emtricitabine), Chronic hepatitis B |
| How it works | Blocks HIV and hepatitis B viruses from copying themselves. | A fake DNA building block that stops HIV and hepatitis B copying themselves. |
| Starts working | Weeks | — |
| Half-life | 5–7 hours (intracellular 18–22 hours) | About 17 hours in plasma |
| Typical adult dose | 300 mg once a day or 150 mg twice a day for HIV; 100 mg once a day for hepatitis B. | 300 mg (245 mg tenofovir disoproxil) once a day. |
| Forms | Tablet, Oral solution, Fixed-dose combinations | Tablet, Combination tablets |
| Common side effects | Headache, Nausea, Tiredness, Cough | Nausea, Diarrhoea, Headache, Dizziness |
| Serious side effects | Hepatitis flare on stopping in co-infected people, Lactic acidosis (rare), Pancreatitis in children | Kidney damage, Bone thinning, Hepatitis B flare if stopped suddenly |
| Don't take if | Taking emtricitabine (same class) | — |
| Alcohol | Best to limit. Alcohol adds to liver strain, particularly in hepatitis B. | — |
| Pregnancy | Generally considered safeWidely used in pregnancy within HIV regimens. | Generally considered safeWidely used in pregnancy for HIV and hepatitis B. |
| Breastfeeding | Usually avoidedIn high-income countries breastfeeding is not advised with HIV; where formula is unsafe, guidelines support breastfeeding with treatment. | — |
| In use since | — | 2001 |
| Brand names | United States: EpivirUnited Kingdom: EpivirIndia: Lamivir, Lamivudine (generic) | United States: Viread, Truvada (with emtricitabine)United Kingdom: Viread, TruvadaIndia: Tenvir |
| Legal status | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule H | — |
| ATC code | J05AF05 | J05AF07 |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker